An Atlas of Schizophrenia - The encyclipedia of visual medicine series

[1]  D. Umbricht,et al.  Atypical antipsychotics in the treatment of schizophrenia. , 2003, Swiss medical weekly.

[2]  R. Emsley,et al.  Low dose typical antipsychotics — a brief evaluation , 2001 .

[3]  S. Kapur,et al.  Atypical antipsychotics , 2000, BMJ : British Medical Journal.

[4]  N Freemantle,et al.  Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis , 2000, BMJ : British Medical Journal.

[5]  K. Jain.  An assessment of iloperidone for the treatment of schizophrenia , 2000, Expert opinion on investigational drugs.

[6]  T. Lempérière,et al.  Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group* , 2000, European Psychiatry.

[7]  E. Kringlen.  Twin studies in schizophrenia with special emphasis on concordance figures. , 2000, American journal of medical genetics.

[8]  C. Coulouvrat,et al.  Safety profile of amisulpride in short‐ and long‐term use , 2000, Acta psychiatrica Scandinavica. Supplementum.

[9]  W. Rein,et al.  Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group. , 2000, International clinical psychopharmacology.

[10]  C. Coulouvrat,et al.  Safety of amisulpride (Solian): a review of 11 clinical studies. , 1999, International clinical psychopharmacology.

[11]  David R. Sibley,et al.  Interactions of the Novel Antipsychotic Aripiprazole (OPC-14597) with Dopamine and Serotonin Receptor Subtypes , 1999, Neuropsychopharmacology.

[12]  S. Potkin,et al.  Ziprasidone 80 mg/day and 160 mg/day in the Acute Exacerbation of Schizophrenia and Schizoaffective Disorder: A 6-Week Placebo-Controlled Trial , 1999, Neuropsychopharmacology.

[13]  J. Danion,et al.  Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group. , 1999, The American journal of psychiatry.

[14]  R. Murray,et al.  Heritability estimates for psychotic disorders: the Maudsley twin psychosis series. , 1999, Archives of general psychiatry.

[15]  J. Feighner,et al.  Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial , 1998, Psychopharmacology.

[16]  S. Strakowski,et al.  Attentional improvement following quetiapine fumarate treatment in schizophrenia. , 1998, Schizophrenia research.

[17]  D. Goff,et al.  An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. , 1998, Journal of clinical psychopharmacology.

[18]  R. Tandon,et al.  New atypical antipsychotic medications. , 1998, Journal of psychiatric research.

[19]  G. Tollefson,et al.  Depressive signs and symptoms in schizophrenia: A prospective blinded trial of olanzapine and haloperidol , 1998, European Neuropsychopharmacology.

[20]  A. Puech,et al.  Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group. , 1998, Acta Psychiatrica Scandinavica.

[21]  T. Barnes,et al.  One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms , 1997, British Journal of Psychiatry.

[22]  H. Möller,et al.  Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol , 1997, Psychopharmacology.

[23]  L. Griffiths,et al.  Iloperidone: Preclinical Profile and Early Clinical Evaluation , 1997 .

[24]  S. Marder,et al.  Does risperidone improve verbal working memory in treatment-resistant schizophrenia? , 1997, The American journal of psychiatry.

[25]  P. Rosenzweig,et al.  Effects of haloperidol and amisulpride on motor and cognitive skill learning in healthy volunteers , 1997, Psychopharmacology.

[26]  R. Tamura,et al.  Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. , 1997, The American journal of psychiatry.

[27]  R. Bilder.  Neurocognitive Impairment in Schizophrenia and how it Affects Treatment Options , 1997, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[28]  Y. Lecrubier,et al.  Amisulpride versus imipramine and placebo in dysthymia and major depression. Amisulpride Study Group. , 1997, Journal of affective disorders.

[29]  B. Gallhofer,et al.  Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs , 1996, European Neuropsychopharmacology.

[30]  A. Rothschild,et al.  Management of psychotic, treatment-resistant depression. , 1996, The Psychiatric clinics of North America.

[31]  P. McKenna,et al.  Successful Treatment of Tardive Dystonia with Clozapine and Clonazepam , 1996, British Journal of Psychiatry.

[32]  H. Meltzer,et al.  Neuropsychologic deficits in schizophrenia : Relation to social function and effect of antipsychotic drug treatment , 1996 .

[33]  J. Calabrese,et al.  Clozapine for treatment-refractory mania. , 1996, The American journal of psychiatry.

[34]  W. Carpenter.  Maintenance therapy of persons with schizophrenia. , 1996, The Journal of clinical psychiatry.

[35]  M. D. Banov,et al.  Is clozapine a mood stabilizer? , 1995, The Journal of clinical psychiatry.

[36]  Y. Lecrubier,et al.  Treatment of Negative Symptoms in Schizophrenia with Amisulpride , 1995, British Journal of Psychiatry.

[37]  Y. Lecrubier,et al.  Improvement of some schizophrenic deficit symptoms with low doses of amisulpride. , 1995, The American journal of psychiatry.

[38]  H. Meltzer,et al.  Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. , 1995, The American journal of psychiatry.

[39]  J. Lieberman,et al.  Clozapine, negative symptoms, and extrapyramidal side effects. , 1994, The Journal of clinical psychiatry.

[40]  H. Meltzer,et al.  Effects of clozapine on cognitive function in schizophrenia. , 1994, The Journal of clinical psychiatry.

[41]  J. Calabrese,et al.  Clozapine in treatment-refractory mood disorders. , 1994, The Journal of clinical psychiatry.

[42]  J. Gerlach,et al.  Motor and mental side effects of clozapine. , 1994, The Journal of clinical psychiatry.

[43]  C. Tamminga,et al.  Clozapine in tardive dyskinesia: observations from human and animal model studies. , 1994, The Journal of clinical psychiatry.

[44]  M. D. Banov,et al.  Clozapine therapy in refractory affective disorders: polarity predicts response in long-term follow-up. , 1994, The Journal of clinical psychiatry.

[45]  R. Conley,et al.  Clozapine response varies in deficit vs non-deficit schizophrenic subjects , 1994, Biological Psychiatry.

[46]  L. Friedman,et al.  Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine , 1993, Biological Psychiatry.

[47]  R. Tandon,et al.  Covariance of positive and negative symptoms during neuroleptic treatment in schizophrenia: A replication , 1993, Biological Psychiatry.

[48]  J. Lieberman,et al.  The Effects of Clozapine on Tardive Dyskinesia , 1991, British Journal of Psychiatry.

[49]  I. Gottesman.  Schizophrenia Genesis: The Origins of Madness , 1990 .

[50]  L. Wynne,et al.  Genetic and psychosocial factors in schizophrenia: the Finnish Adoptive Family Study. , 1987, Schizophrenia bulletin.

[51]  J. Shields,et al.  Obstetric complications and twin studies of schizophrenia: clarifications and affirmations. , 1977, Schizophrenia bulletin.

[52]  R. Kendell,et al.  Companion to Psychiatric Studies , 1973 .

[53]  M. Fischer.  Genetic and environmental factors in schizophrenia. A study of schizophrenic twins and their families. , 1973, Acta psychiatrica Scandinavica. Supplementum.

[54]  M. G. Allen,et al.  Psychopathology in 15,909 pairs of veteran twins: evidence for a genetic factor in the pathogenesis of schizophrenia and its relative absence in psychoneurosis. , 1969, The American journal of psychiatry.